DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02650596

UnknownPhase NA

Effects of GLP-1 on Chronic Heart Failure

Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes

Lead sponsor

Shi Yang

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

68

estimated

Study population

Heart failure, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Left ventricular ejection fraction

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02650596
Org study ID301nlxnk

Timeline

Milestones

Study first posted2016-01-08estimated
Last update posted2016-01-08estimated
Study start2016-01 (month precision)
Primary completion2018-02estimated (month precision)
Study completion2018-02estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Heart failureType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Chronic heart failure patients with type 2 diabetes (NYHA-class I, II or III) were eligible for the study

Exclusion criteria

•CHF (NYHA class IV)
•Type 1 diabetes
•Hospitalisation due to incompensated heart disease within 30 days prior to randomisation
•Myocardial infarction within the past 3 months before screening
•Coronary revascularisation within the past 3 months before screening
•Atrial fibrillation with ventricular frequency >100/min in rest
•ECG suggestive of malignant ventricular arrhythmia
•Prolonged QT-interval (>500 ms)
•Valvular heart disease
•Current myocardial or pericardial infection
•Obstructive hypertrophic cardiomyopathy
•Cancer unless in complete remission for ≥5 years
•Acute pancreatitis
•Compromised kidney function (eGFR <30 mL/min), dialysis or kidney transplantation
•History of thyroidea adenoma or carcinoma

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Heart failure
3
Safety / tolerability / PK
1

Heart failure

3 endpoints
Primary/protocol endpoint

left ventricular ejection fraction measured by 3D echocardiography

Time frame:3 months

descriptive, improvement

Secondary/protocol endpoint

plasma NT-proBNP levels

Time frame:3 months

NT-proBNP, change

change from baseline, improvement

Secondary/protocol endpoint

a change in 6-minute walk distance

Time frame:3 months

6-minute walk distance

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

differences in the incidences of treatment-emergent adverse events

Time frame:3 months

Treatment-emergent AEs (any)

event count, event

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.